View all dosages and compare prices:

Buy Retatrutide — all dosages →
🧬PEN PEPTIDE · Triple agonist GLP-1/GIP/glucagon

Retatrutide 6 mg

PEN PEPTIDE · Triple agonist

Next-generation triple agonist · 6 mg · Pre-Mixed Stabilized Pen · PEN PEPTIDE

6 mg
Out of stock

Retatrutide 6 mg from PEN PEPTIDE — stabilized pen injector with triple agonist GLP-1/GIP/glucagon. 120 units of 50 mcg each. Starting dose for course initiation. MSSPT technology — stable formula.

In short: Retatrutide 6 mg (PEN PEPTIDE)

Delivery across Ukraine — Nova Poshta, 1–3 days; Kyiv — courier, 1–2 hours. Cold chain 2–8°C. 24/7 specialist support included in the price. Order on the official DOZA website: doza.clinic.

Active ingredientретатрутид (retatrutide)
Dosage6 mg
Form factorPen
Course~3 weeks (at starting dose 2 mg/week)
👨‍⚕️

Specialist support included in the price

A personal DOZA specialist guides you throughout the entire course — from first consultation to results.

🧬

Triple agonist — next generation

Retatrutide — a triple GLP-1/GIP/glucagon agonist. Investigational Phase 3 molecule by Eli Lilly. Not approved by FDA/EMA.

🏭

Manufacturer: PEN PEPTIDE

PEN PEPTIDE — a brand of peptide products.

Free consultation

Benefits

  • ✓Triple mechanism of action — only agonist GLP-1 + GIP + glucagon
  • ✓Starting dose — ideal for course initiation (6 mg = 3 doses of 2 mg)
  • ✓Pre-Mixed stabilized pen — ready solution, no reconstitution needed
  • ✓MSSPT technology — tolerant to short-term temperature fluctuations
  • ✓Purity ≥98% — GMP-certified production in Europe
  • ✓Up to 28.3% weight loss over 80 weeks on the 12 mg/week dose (Phase 3 TRIUMPH-1, topline 2026); Phase 2: up to 24% over 48 weeks (NEJM 2023)
  • ✓Delivery in thermal box with cold elements (2–8°C) across Ukraine

Retatrutide 6 mg (PEN PEPTIDE) — detailed description

Retatrutide 6 mg from PEN PEPTIDE — triple agonist of GLP-1, GIP and glucagon receptors in a stabilized pen injector.

The 6 mg pen contains 120 units of 50 mcg each. Dosage table:

• 1 unit = 50 mcg

• 20 units = 1 mg

• 40 units = 2 mg

Ideal for starting a course — allows precise dosing of the starting 2 mg dose and gradual titration.

Formula stabilized using MSSPT (Molecular Structure Stabilization Process Technology) — maintains structural integrity and bioactivity even with temporary temperature deviations above 8°C during transportation.

Purity ≥98%. Manufactured in certified GMP laboratories in Europe.

Important: 6 mg is the total pen content of the active substance, not the weekly dose. In Phase 3 TRIUMPH, weekly doses ranged 2–12 mg (2 mg start, escalation every 4 weeks to target doses of 4/9/12 mg); the −28.3% result at 80 weeks (TRIUMPH-1, topline 2026) was achieved on the 12 mg/week dose.

Retatrutide (LY3437943) is an investigational molecule developed by Eli Lilly. This PEN PEPTIDE product is manufactured by a third party and is not manufactured, supplied or approved by Eli Lilly.

How it works — mechanism of action

Retatrutide — the only triple agonist GLP-1 + GIP + glucagon. Acts on three receptors simultaneously:

1. GLP-1 — reduces appetite, slows gastric emptying, regulates glucose levels.

2. GIP — enhances GLP-1 effects and improves fat tissue metabolism.

3. Glucagon — activates lipolysis (fat breakdown) and thermogenesis (calorie burning).

In Phase 3 TRIUMPH-1 (topline 2026), participants on 12 mg lost an average of 28.3% body weight over 80 weeks (efficacy estimand) — the highest published result in the GLP-1 class. Phase 2 (NEJM 2023): up to 24% over 48 weeks.

Dosage

Standard starting dose: 2 mg once weekly subcutaneously.

Gradual titration: 2 mg → 4 mg → 6 mg → 9 mg → 12 mg (Phase 3 TRIUMPH protocol, escalation every 4 weeks) depending on tolerability and results.

Subcutaneous injection in abdomen, thigh or shoulder area. Same day of the week.

Do not increase dose until appetite returns. Maintain balanced nutrition.

What's in the kit

Стабілізована шприц-ручка PEN PEPTIDE Retatrutide 6 мг.

• 1 ручка = 6 мг ретатрутиду (120 юнітів × 50 мкг)

• 1 юніт = 50 мкг, 20 юнітів = 1 мг, 40 юнітів = 2 мг

• Pre-Mixed — готовий розчин, не потребує розведення

• Технологія MSSPT — стабілізована формула

• Чистота ≥98%

Composition

Діюча речовина: ретатрутид (retatrutide) 6 мг загалом у ручці (120 юнітів × 50 мкг).

Стабілізована формула (MSSPT — Molecular Structure Stabilization Process Technology):

• Оптимізовані буферні компоненти для підтримки стабільного pH

• Антиоксиданти для запобігання окислювальній деградації

• Стабілізуючі агенти для запобігання агрегації

Чистота ≥98%. Вироблено на GMP-сертифікованих лабораторіях.

Storage

Зберігати в холодильнику при температурі 2–8°C. Не заморожувати.

Стабілізована формула (MSSPT) — толерантна до короткочасних відхилень температури вище 8°C під час транспортування.

Зберігати ручку в оригінальній упаковці для захисту від світла.

Після першого використання — зберігати при 2–8°C, використати протягом терміну придатності.

Не зберігати з приєднаною голкою.

Тільки для підшкірного введення.

Клінічні дослідження

Retatrutide (LY3437943 6 mg) — потрійний агоніст GLP-1 + GIP + глюкагон Eli Lilly. Phase 3 TRIUMPH-1/2/3: topline 2026, до −28.3% ваги за 80 тижнів (12 мг). Подача BLA у FDA — план Q1 2027. На /research зібрана доказова база Phase 2/3 та статус trials.

Retatrutide is an investigational drug. Phase 3 TRIUMPH-1/2/3 topline results reported in 2026; US BLA planned Q1 2027. Not approved by FDA, EMA or МОЗ України as of August 2026.

View full клінічні дослідження database →

Titration protocol to 6 mg (retatrutide (triple GLP-1 / GIP / glucagon agonist))

Weeks 1–4
2 mg

Starting dose for all Phase 3 TRIUMPH participants

Weeks 5–8
4 mg

First escalation (target dose for the 4 mg group)

Weeks 9–12
6 mg← this dose

Intermediate escalation step

Weeks 13–16
9 mg

Target dose for the 9 mg group

Weeks 17+
12 mg

Maximum TRIUMPH-1 target dose (−28.3% at 80 weeks)

Injection once weekly (per study protocol), subcutaneous (abdomen, thigh or upper arm). Expected weight loss at the 12 mg/week dose: -28.3% over 80 weeks (Phase 3 TRIUMPH-1, topline 2026) (based on clinical studies).

Who is Retatrutide 6 mg for

  • Retatrutide is an investigational drug (Phase 3), not yet approved by the FDA/EMA
  • Triple GLP-1 / GIP / glucagon agonist — a unique mechanism of action
  • For patients for whom single (Ozempic) or dual (Mounjaro) agonists did not deliver enough effect
  • Strictly under medical supervision

Retatrutide 6 mg — compared to other doses

  • Retatrutide 12 mg showed -28.3% weight loss over 80 weeks in Phase 3 TRIUMPH-1 (topline 2026, efficacy estimand); Phase 2 (NEJM 2023): ~24% over 48 weeks
  • In separate trials the numeric result is higher than Mounjaro 15 mg (-22.5%, SURMOUNT-1), but a direct head-to-head trial (NCT06662383) is still ongoing — clinical superiority has not been established
  • Key difference: retatrutide activates the glucagon receptor, increasing energy expenditure
  • Phase 3 results are topline/press-release level — full peer-reviewed publications pending; BLA (US) planned Q1 2027

FAQ about Retatrutide 6 mg (PEN PEPTIDE)

Valentyna Tytorenko

You can buy Retatrutide 6 mg PEN PEPTIDE at DOZA — specialized online service. Orders are placed through the website cart or Telegram. Delivery across Ukraine with cold chain compliance 2–8°C.

Valentyna Tytorenko

Diploma-certified endocrinologist, certified dietitian and nutritionist

Ready to start?

Free consultation

DOZA client reviews for Retatrutide 6 mg (PEN PEPTIDE)

★★★★★Olena M.March 2026

Retatrutide 6 mg (PEN PEPTIDE) — noticeable results in just 3 weeks. Cold chain delivery, everything neat. Thank you, DOZA!

★★★★★Dmytro S.April 2026

Ordering Retatrutide 6 mg (PEN PEPTIDE) via DOZA — fast delivery across Ukraine. Consultant helped choose the right dose. Triple agonist works more effectively.

All client results →

Before/after photos · numbers · timelines · reviews

🏆

Buy Retatrutide 6 mg in Ukraine

Buy Retatrutide 6 mg (PEN PEPTIDE) — next-generation triple GLP-1/GIP/glucagon agonist from DOZA. Next-generation triple agonist · 6 mg · Pre-Mixed Stabilized Pen · PEN PEPTIDE. Dosage 6 mg — for optimal therapeutic effect. Order via DOZA online service, delivery 1–2 days.

Free DOZA specialist consultation. Available 24/7.

Buy Retatrutide 6 mg (PEN PEPTIDE) in Ukraine — DOZA online service with delivery in 1–2 days. Specialist consultation included.

Information verified

Valentyna Tytorenko

Diploma-certified endocrinologist, certified dietitian and nutritionist

Melnyk Natalia

Gastroenterologist

⚠️ Retatrutide is an investigational product currently undergoing Phase 3 clinical trials. Results may vary. Consult a specialist before starting the program. Retatrutide is currently undergoing large-scale Phase 3 clinical trials (the TRIUMPH program). Final regulatory approval is expected after the completion of trials.